ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Dasatinib and nilotinib, two newer drugs with higher potency than imatinib against BCR-ABL and activity against most imatinib-resistant BCR-ABL mutations, have demonstrated superior efficacy compared with imatinib for first-line chronic-phase CML treatment in randomized phase III trials[2,3].